** Indian drugmaker's shares DIVI.NS slump as much as 8.8%
to 4,747.80 rupees, on track for worst day in over 1-1/2 years
** U.S.-based pharma giant Pfizer PFE.N on Friday said its
antiviral pill slashes risk of severe COVID-19 by 89%,
surpassing Merck & Co's MRK.N pill, molnupiravir which halves
the chance of hospitalization or death for adults at risk of
severe COVID-19 urn:newsml:reuters.com:*:nL1N2RW0N5
** Analysts at Jefferies say that Pfizer's drug could pose a
risk to Divi's prospects as it makes the active pharmaceutical
ingredient (API) of molnupiravir
** Jefferies also added that the company may not be immune
to rising raw material prices in coming quarters and does not
see its margins improving
** Divi's which has already begun supplying molnupiravir
didn't specify the reason for sluggishness in their generic APIs
business (second quarter in a row) during earnings call - Ambit
Capital
** Continued sluggishness in the generic API segment could
pose risk to Divi's near-term forecast and valuations - Ambit
** On Friday, Divi's reported 17% rise in Q2 consolidated
net profit to 6.06 bln rupees ($81.68 million)
** Despite session's drop, DIVI stock is still up ~24% YTD
($1 = 74.1900 Indian rupees)
(Reporting by Shivani Singh in Bengaluru)
((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))